Elicio Therapeutics Reports $39.6 Million Net Loss and Advances ELI-002 7P in 10-K Filing

**Elicio Therapeutics Reports Financial Results and Clinical Developments in Form 10-K Filing**

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, released its Form 10-K filing, detailing its financial performance and operational activities. The company reported a net loss of $39.6 million for the year ended December 31, 2025, compared to a net loss of $51.9 million for the previous year. Research and development expenses totaled $24.9 million, a decrease from $33.7 million in 2024, while general and administrative expenses increased to $12.8 million from $11.3 million. The decrease in research and development expenses was primarily due to lower clinical costs as patients progressed into the observation phase of the Phase 2 study of ELI-002 7P. The increase in general and administrative expenses was primarily due to an increase in headcount for 2025.

The company's financial position included cash and cash equivalents of $18.6 million as of December 31, 2025. The company has an accumulated deficit of $233.7 million. The company has identified that it will need to raise additional capital to fund operations for at least twelve months following the issuance of the consolidated financial statements, which raises substantial doubt about its ability to continue as a going concern. The company plans to address this condition through the sale of its common stock or other securities in public offerings and/or private placements, debt financings, or through other capital sources, including licensing arrangements, partnerships and collaborations with other companies or other strategic transactions.

Operationally, Elicio continued to advance its lead product candidate, ELI-002 7P, a lymph node-targeted immunotherapy designed to stimulate an immune response against mKRAS-driven cancers. The company completed enrollment in its AMPLIFY-7P Phase 2 trial in mKRAS-driven pancreatic ductal adenocarcinoma (PDAC) in December 2024. In August 2025, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue to the final analysis without modifications, confirming the favorable safety profile of ELI-002 7P. The final disease-free survival (DFS) analysis is anticipated to occur in the first half of 2026. The company also announced robust mKRAS-specific T cell responses in 99% of evaluable patients in the ongoing Phase 2 AMPLIFY-7P trial.

Elicio is also advancing its preclinical pipeline, including ELI-007 for mutant BRAF-driven cancers and ELI-008 for mutant TP53-expressing cancers. The company intends to seek collaboration opportunities to advance these programs into Phase 1 trials. The company's strategy includes expanding ELI-002 7P clinical development to other KRAS-driven cancers and realizing the full value of its Amphiphile (AMP) technology through collaborations. The company anticipates the event-driven primary DFS analysis for the AMPLIFY-7P study to occur in the first half of 2026, depending on event accrual.